News | December 23, 2025
Cupid reduces promoter pledged stake to 20%
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The combination also outperformed chemotherapy on another important secondary endpoint
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Subscribe To Our Newsletter & Stay Updated
